123 related articles for article (PubMed ID: 20690686)
21. Inhibition of vascular adhesion protein-1 suppresses endotoxin-induced uveitis.
Noda K; Miyahara S; Nakazawa T; Almulki L; Nakao S; Hisatomi T; She H; Thomas KL; Garland RC; Miller JW; Gragoudas ES; Kawai Y; Mashima Y; Hafezi-Moghadam A
FASEB J; 2008 Apr; 22(4):1094-103. PubMed ID: 18032635
[TBL] [Abstract][Full Text] [Related]
22. Vascular adhesion protein-1 plays an important role in postischemic inflammation and neuropathology in diabetic, estrogen-treated ovariectomized female rats subjected to transient forebrain ischemia.
Xu HL; Salter-Cid L; Linnik MD; Wang EY; Paisansathan C; Pelligrino DA
J Pharmacol Exp Ther; 2006 Apr; 317(1):19-29. PubMed ID: 16339390
[TBL] [Abstract][Full Text] [Related]
23. [Synthesis of hydrazino alcohols with anti-inflammatory activity].
Lázár L; Szakonyi Z; Forró E; Palkó M; Zalán Z; Szatmári I; Fülöp F
Acta Pharm Hung; 2004; 74(1):11-8. PubMed ID: 15524044
[TBL] [Abstract][Full Text] [Related]
24. Bioluminescent method for assaying multiple semicarbazide-sensitive amine oxidase (SSAO) family members in both 96- and 384-well formats.
Peet GW; Lukas S; Hill-Drzewi M; Martin L; Rybina IV; Roma T; Shoultz A; Zhu X; Cazacu D; Kronkaitis A; Baptiste A; Raudenbush BC; August EM; Modis LK
J Biomol Screen; 2011 Oct; 16(9):1106-11. PubMed ID: 21844327
[TBL] [Abstract][Full Text] [Related]
25. Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment.
Inoue T; Morita M; Tojo T; Nagashima A; Moritomo A; Miyake H
Bioorg Med Chem; 2013 Jul; 21(13):3873-81. PubMed ID: 23664164
[TBL] [Abstract][Full Text] [Related]
26. PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo.
Foot JS; Yow TT; Schilter H; Buson A; Deodhar M; Findlay AD; Guo L; McDonald IA; Turner CI; Zhou W; Jarolimek W
J Pharmacol Exp Ther; 2013 Nov; 347(2):365-74. PubMed ID: 23943052
[TBL] [Abstract][Full Text] [Related]
27. Novel pyridazinone inhibitors for vascular adhesion protein-1 (VAP-1): old target-new inhibition mode.
Bligt-Lindén E; Pihlavisto M; Szatmári I; Otwinowski Z; Smith DJ; Lázár L; Fülöp F; Salminen TA
J Med Chem; 2013 Dec; 56(24):9837-48. PubMed ID: 24304424
[TBL] [Abstract][Full Text] [Related]
28. Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo.
Marttila-Ichihara F; Smith DJ; Stolen C; Yegutkin GG; Elima K; Mercier N; Kiviranta R; Pihlavisto M; Alaranta S; Pentikäinen U; Pentikäinen O; Fülöp F; Jalkanen S; Salmi M
Arthritis Rheum; 2006 Sep; 54(9):2852-62. PubMed ID: 16947396
[TBL] [Abstract][Full Text] [Related]
29. Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications.
Stolen CM; Madanat R; Marti L; Kari S; Yegutkin GG; Sariola H; Zorzano A; Jalkanen S
FASEB J; 2004 Apr; 18(6):702-4. PubMed ID: 14977883
[TBL] [Abstract][Full Text] [Related]
30. Small-molecule inhibitors of vascular adhesion protein-1 reduce the accumulation of myeloid cells into tumors and attenuate tumor growth in mice.
Marttila-Ichihara F; Castermans K; Auvinen K; Oude Egbrink MG; Jalkanen S; Griffioen AW; Salmi M
J Immunol; 2010 Mar; 184(6):3164-73. PubMed ID: 20154208
[TBL] [Abstract][Full Text] [Related]
31. Structure-activity relationships of SSAO/VAP-1 arylalkylamine-based substrates.
Yraola F; Zorzano A; Albericio F; Royo M
ChemMedChem; 2009 Apr; 4(4):495-503. PubMed ID: 19266512
[TBL] [Abstract][Full Text] [Related]
32. [Vascular adhesion protein-1 (VAP-1) in inflammatory process].
Pietruczuk M; Pietruczuk A; Zajkowska J; Pancewicz S; Hermanowska-Szpakowicz T
Przegl Lek; 2006; 63(4):220-2. PubMed ID: 17083159
[TBL] [Abstract][Full Text] [Related]
33. Siglec-9 is a novel leukocyte ligand for vascular adhesion protein-1 and can be used in PET imaging of inflammation and cancer.
Aalto K; Autio A; Kiss EA; Elima K; Nymalm Y; Veres TZ; Marttila-Ichihara F; Elovaara H; Saanijoki T; Crocker PR; Maksimow M; Bligt E; Salminen TA; Salmi M; Roivainen A; Jalkanen S
Blood; 2011 Sep; 118(13):3725-33. PubMed ID: 21821708
[TBL] [Abstract][Full Text] [Related]
34. Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target.
Dunkel P; Gelain A; Barlocco D; Haider N; Gyires K; Sperlágh B; Magyar K; Maccioni E; Fadda A; Mátyus P
Curr Med Chem; 2008; 15(18):1827-39. PubMed ID: 18691041
[TBL] [Abstract][Full Text] [Related]
35. Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate.
Kivi E; Elima K; Aalto K; Nymalm Y; Auvinen K; Koivunen E; Otto DM; Crocker PR; Salminen TA; Salmi M; Jalkanen S
Blood; 2009 Dec; 114(26):5385-92. PubMed ID: 19861682
[TBL] [Abstract][Full Text] [Related]
36. The role of two distinct endothelial molecules, vascular adhesion protein-1 and peripheral lymph node addressin, in the binding of lymphocyte subsets to human lymph nodes.
Salmi M; Hellman J; Jalkanen S
J Immunol; 1998 Jun; 160(11):5629-36. PubMed ID: 9605169
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and structure activity relationships of glycine amide derivatives as novel Vascular Adhesion Protein-1 inhibitors.
Yamaki S; Suzuki D; Fujiyasu J; Neya M; Nagashima A; Kondo M; Akabane T; Kadono K; Moritomo A; Yoshihara K
Bioorg Med Chem; 2017 Jan; 25(1):187-201. PubMed ID: 27810440
[TBL] [Abstract][Full Text] [Related]
38. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases.
Kurkijärvi R; Adams DH; Leino R; Möttönen T; Jalkanen S; Salmi M
J Immunol; 1998 Aug; 161(3):1549-57. PubMed ID: 9686623
[TBL] [Abstract][Full Text] [Related]
39. Origins of serum semicarbazide-sensitive amine oxidase.
Stolen CM; Yegutkin GG; Kurkijärvi R; Bono P; Alitalo K; Jalkanen S
Circ Res; 2004 Jul; 95(1):50-7. PubMed ID: 15178639
[TBL] [Abstract][Full Text] [Related]
40. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
